The next-generation biomarker, urine ALCAM, distinguishes active LN (ALN) from non-active LN (quiescent or no prior nephritis), and previous LN, alluding to its role in renal SLE (11, 12). The gene discussed is ALCAM; the disease is lobular neoplasia.